3Scan’s Nada Rastad: crossing the line and patenting robotics

Given the novel applications of emerging technologies such as robotics, it might be assumed that obtaining patents will be easy. But, as Nada Rastad, general counsel at 3Scan, has discovered, that’s not quite true.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

Americas

Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026

28 April 2026 An event for IP, legal and compliance leaders to address the growing threat of trade secret misappropriation heads to San Jose.

Americas

Amneal acquires biopharma ahead of $300bn patent wave

23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.

More features

CureVac targets Moderna with 10-patent suit over Spikevax

Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026

Amneal acquires biopharma ahead of $300bn patent wave

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

Squires refuses to resurrect HydraFacial patent review

Litigator from Brown Rudnick moves firms to chair practice

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

3Scan’s Nada Rastad: crossing the line and patenting robotics

More on this story

Editor's picks

Editor's picks

More features